First Acute COPD Exacerbation a Significant Risk for Death within 4 Years

Web Exclusives
Wayne Kuznar

More than one third of patients with a first acute exacerbation of chronic obstructive pulmonary disease (COPD) died within 4 years in a recent small study presented by Kamil Klenha, MD, and colleagues from the Regional Hospital Tabor in the Czech Republic.

The study included 80 patients with a first acute COPD exacerbation who met the GOLD (Global Initiative for Chronic Obstructive Lung Disease) criteria for hospitalization. The patients were treated in a nonintensive care unit ward; the cause of exacerbation was infectious in 57.5% of the patients and noninfectious in 42.5%.

Patients were treated according to current recommendations and were monitored every 3 to 6 months in the hospital’s outpatient clinic. By year 4 of follow-up, 35% of the group had died—7 patients during the first year, 8 during the second year, 7 during the third year, and 6 during the fourth year.

The mortality in this case series was not as high as in other series, some of which are as high as 59%; this likely reflects the absence of patients with the most severe disease, because no patients required treatment in an intensive care unit ward, according to the researchers. Significant predictors of mortality were:

  • Older age
  • Worsening lung function as determined by a lower forced expiratory volume in 1 second
  • Frequent acute exacerbations
  • A history of smoking.

Current smokers, as well as those who quit <10 years earlier, had 3.8 times the risk for death compared with lifelong nonsmokers or those who quit ≥10 years earlier.

Hypoxemia and/or hypercapnia were associated with a more than doubling of the risk for mortality.

The researchers concluded that their data confirm the seriousness of an acute exacerbation.

Related Items
Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Conference Highlights ASH
Apamistamab-Based Lymphodepleting Regimen Before CAR T-Cell Therapy May Prevent Cytokine Release Syndrome
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Emerging Therapies
First-Line Acalabrutinib-Based Triplet Therapy Leads to Undetectable Minimal Residual Disease in CLL
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
Investigational Oral Form of Azacitidine Improves Survival Maintenance Therapy in Patients with Acute Myeloid Leukemia
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
All-Oral Time-Limited Combination Treatment for CLL or SLL Shows Early Impressive Efficacy
Wayne Kuznar
February 2020 Vol 13, Special Issue published on February 25, 2020 in Leukemia
Last modified: February 14, 2019
  •  Association for Value-Based Cancer Care
  • Oncology Practice Management
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Rheumatology Practice Management
  • Urology Practice Management
  • Lynx CME